
ARTV Stock Forecast & Price Target
ARTV Analyst Ratings
Bulls say
Artiva Biotherapeutics Inc. has a promising outlook driven by the strong enrollment figures in their clinical trials, with over a dozen patients reported in August and over 20 anticipated by November, indicating limited safety concerns. The company's pipeline, including the AlloNK therapy aimed at enhancing antibody-dependent cellular cytotoxicity, holds the potential for significantly improved clinical outcomes, which is reflected in the bullish assumptions around durable remissions. Moreover, there is potential for substantial near-term appreciation based on the modest premium in after-hours trading compared to projected cash values, especially as substantial data sets are expected to emerge in the coming months.
Bears say
Artiva Biotherapeutics's financial outlook is negatively impacted by the uncertainty surrounding its lead candidate, AlloNK, with assumptions suggesting a 10% probability of success (POS) due to potential failures in achieving deep B-cell aplasia or tolerability concerns. This scenario indicates a potential downside of approximately 25% to 40% from the company's Base Case estimates. Furthermore, the risks associated with generating additional successful clinical candidates from its NK cell therapy platform compound the company's challenges, contributing to a dim perspective on future revenue generation.
This aggregate rating is based on analysts' research of Artiva Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ARTV Analyst Forecast & Price Prediction
Start investing in ARTV
Order type
Buy in
Order amount
Est. shares
0 shares